《生命科学》 2023, 35(7): 916-924

CAR-T细胞治疗结直肠癌的现状及挑战

罗　霞¹ , 唐语哲² , 胡晓东² , 董靖宇² , 胡　嘉^2,*

¹华中科技大学同济医学院附属同济医院检验科，武汉 430030 ²武汉科技大学生命科学与健康学院，武汉 430065

摘　要：

全球结直肠癌的发病率和致死率居高不下。传统的治疗方案，如手术、化疗或联合治疗可用于治疗早期结直肠癌患者，然而复发性、转移性结直肠癌目前仍然缺乏有效的治疗手段。过继嵌合抗原受体T细胞(chimeric antigen receptor T-cell, CAR-T) 疗法已经在恶性血液肿瘤的治疗中取得了成功，研究人员也开展了CAR-T 细胞用于治疗晚期结直肠癌的研究。本文总结了目前CAR-T 细胞治疗结直肠癌的现状及挑战，汇总了CAR-T 细胞治疗结直肠癌的靶点，阐述了CAR-T 疗法治疗结直肠癌的临床前和临床研究，并对提高CAR-T 细胞疗法治疗结直肠癌的安全性和有效性策略进行综述。

通讯作者：胡　嘉 , Email:hujia123@wust.edu.cn

Current status and challenges of CAR-T therapy in colorectal cancer treatment

LUO Xia¹ , TANG Yu-Zhe² , HU Xiao-Dong² , DONG Jing-Yu² , HU Jia^2,*

¹Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China ²College of Life Sciences and Health, Wuhan University of Science and Technology, Wuhan 430065, China

Abstract:

The incidence and mortality of colorectal cancer (CRC) are high worldwide. Conventional treatment options for early-staged CRC patients include surgery, chemotherapy or combination therapy. However, there is still lack of effective treatments for recurrent and metastatic CRC. Chimeric antigen receptor T (CAR-T) cell therapy has gained great successes in the treatment of hematologic malignancies. Researchers are working to investigate whether CAR-T cells can be used for CRC treatment. In this review, we summarize the current status and challenges, the targets, the completed and ongoing pre-clinical and clinical studies of CAR-T cell therapy in CRC, and review the strategies which can be used to improve its safety and efficacy.

Communication Author：HU Jia , Email:hujia123@wust.edu.cn